All In Biotech

Drug Trial Radar · NCT00196326

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle

Last checked: Nov 19, 2026Latest source record: Nov 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,235

Actual

Start

Jun 2005

Primary completion

Jun 2007

Study completion Jun 2007

Sponsor

Lead sponsor
Duramed ResearchIndustry
Sponsor type
Industry
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.

Conditions

  • Contraception

Interventions

  • DR-1011Drug

    Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" PregnancyTime frame: up to one year
  2. Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" PregnancyTime frame: up to one year

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Duramed Investigational Site

    Huntsville, Alabama

  • Duramed Investigational Site

    Phoenix, Arizona

  • Duramed Investigational Site

    Phoenix, Arizona

  • Duramed Investigational Site

    Phoenix, Arizona

  • Duramed Investigational Site

    Tucson, Arizona

  • Duramed Investigational Site

    San Diego, California

  • Duramed Investigational Site

    San Diego, California

  • Duramed Investigational Site

    Colorado Springs, Colorado

  • Duramed Investigational Site

    Colorado Springs, Colorado

  • Duramed Investigational Site

    Denver, Colorado

  • Duramed Investigational Site

    New London, Connecticut

  • Duramed Investigational Site

    Coral Cables, Florida

  • Duramed Investigational Site

    Hollywood, Florida

  • Duramed Investigational Site

    Jacksonville, Florida

  • Duramed Investigational Site

    Leesburg, Florida

  • Duramed Investigational Site

    Miami, Florida

  • Duramed Investigational Site

    Palm Springs, Florida

  • Duramed Investigational Site

    Sarasota, Florida

  • Duramed Investigational Site

    Tampa, Florida

  • Duramed Investigational Site

    Decatur, Georgia

  • Duramed Investigational Site

    Douglasville, Georgia

  • Duramed Investigational Site

    Boise, Idaho

  • Duramed Investigational Site

    Chicago, Illinois

  • Duramed Investigational Site

    Shawnee Mission, Kansas

  • Duramed Investigational Site

    Topeka, Kansas

  • Duramed Investigational Site

    Louisville, Kentucky

  • Duramed Investigational Site

    Kansas City, Missouri

  • Duramed Investigational Site

    St Louis, Missouri

  • Duramed Investigational Site

    Lawrenceville, New Jersey

  • Duramed Investigational Site

    Moorestown, New Jersey

  • Duramed Investigational Site

    New Brunswick, New Jersey

  • Duramed Investigational Site

    Rochester, New York

  • Duramed Investigational Site

    Charlotte, North Carolina

  • Duramed Investigational Site

    Wilmington, North Carolina

  • Duramed Investigational Site

    Winston-Salem, North Carolina

  • Duramed Investigational Site

    Columbus, Ohio

  • Duramed Investigational Site

    Columbus, Ohio

  • Duramed Investigational Site

    Oklahoma City, Oklahoma

  • Duramed Investigational Site

    Medford, Oregon

  • Duramed Investigational Site

    Philadelphia, Pennsylvania

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.